Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Machine learning-based sequential analysis to assist selection between VMP & Rd for NDMM

Jamin Koo, PhD, Stanford University, Stanford, CA, discusses a recent study which used machine learning to assist in selecting between bortezomib, melphalan, and prednisone (VMP) therapy and lenalidomide-dexamethasone (Rd) in patients with multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Cofounder of ImpriMed